The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

This paper discusses updated guidance on new migraine treatments for adults. The American Headache Society aimed to include recent research, expert consensus, and patient perspectives. Previous Consensus Statements had outlined treatment options for migraines. This update is based on expanded evidence and expert consensus on postapproval usage. The process involved reviewing treatment efficacy, safety, and clinical use. Recommendations were made without formal guidelines. Four steps were undertaken to create this update. These included reviewing data, proposing updates, gathering feedback, and integrating insights. Since the last Consensus Statement, no new evidence changed established treatment principles. New acute treatments include two CGRP receptor antagonists: ubrogepant and rimegepant. The integration of these treatments should consider patient preferences and potential benefits. This comprehensive approach aims to enhance migraine management for diverse patients and ensure treatments are effective and personalized. Clinical relevance: This research emphasizes the importance of integrating new migraine treatments into clinical practice.